Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis

This randomized, double-blind study assessed the antifracture efficacy and safety of intermittent intravenous (IV) ibandronate versus oral daily risedronate in Japanese patients with primary osteoporosis. Ambulatory patients aged ≥60 years were randomized to receive 0.5 or 1 mg/month IV ibandronate...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Nakamura, Toshitaka, Nakano, Tetsuo, Ito, Masako, Hagino, Hiroshi, Hashimoto, Junko, Tobinai, Masato, Mizunuma, Hideki
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2013
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3717162/
https://ncbi.nlm.nih.gov/pubmed/23644930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00223-013-9734-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars